Prot #KTE-C19-107: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Project: Research project

Project Details

StatusActive
Effective start/end date10/12/1810/12/21

Funding

  • DrugDev Inc. (Prot #KTE-C19-107)
  • Kite Pharma, Inc. (Prot #KTE-C19-107)